临床试验的途径
Gateways to clinical trials.
作者信息
Bayes M, Rabasseda X, Prous J R
机构信息
Prous Science, Barcelona, Spain.
出版信息
Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):451-95.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com This issue focuses on the following selection of drugs: A-007, A6, adalimumab, adenosine triphosphate, alefacept, alemtuzumab, AllerVax Ragweed, amphora, anakinra, angiotensin-(1-7), anidulafungin, apomine, aripiprazole, atomoxetine hydrochloride, avanafil; BAL-8557, becatecarin, bevacizumab, biphasic insulin aspart, BMS-188797, bortezomib, bosentan, botulinum toxin type B, brivudine; Calcipotriol/betamethasone dipropionate, caspofungin acetate, catumaxomab, certolizumab pegol, cetuximab, CG-0070, ciclesonide, cinacalcet hydrochloride, clindamycin phosphate/benzoyl peroxide, cryptophycin 52, Cypher; Dabigatran etexilate, darapladib, darbepoetin alfa, decitabine, deferasirox, desloratadine, dexanabinol, dextromethorphan/quinidine sulfate, DMF, drotrecogin alfa (activated), duloxetine hydrochloride; E-7010, edaravone, efalizumab, emtricitabine, entecavir, eplerenone, erlotinib hydrochloride, escitalopram oxalate, estradiol valerate/dienogest, eszopiclone, exenatide, ezetimibe; Fondaparinux sodium, fulvestrant; Gefitinib, gestodene, GYKI-16084; Hyaluronic acid, hydralazine hydrochloride/isosorbide dinitrate; Imatinib mesylate, indiplon, insulin glargine; Juzen-taiho-to; Lamivudine/zidovudine/abacavir sulfate, L-arginine hydrochloride, lasofoxifene tartrate, L-BLP-25, lenalidomide, levocetirizine, levodopa/carbidopa/entacapone, lexatumumab, lidocaine/prilocaine, lubiprostone, lumiracoxib; MAb-14.18, mitoquidone; Natalizumab, neridronic acid, neuradiab; Olpadronic acid sodium salt, omalizumab; p53-DC vaccine, parathyroid hormone (human recombinant), peginterferon alfa-2a, peginterferon alfa-2b, pemetrexed disodium, perifosine, pimecrolimus, prasterone, prasugrel, PRO-2000, Pseudostat; R24, rasburicase, RHAMM R3 peptide, rilonacept, rosuvastatin calcium, rotavirus vaccine, rufinamide; Sabarubicin hydrochloride, SHL-749, sirolimus-eluting stent, SLx-2101, sodium butyrate, sorafenib, SU-6668; TachoSil, tadalafil, taxus, tegaserod maleate, telbivudine, tenofovir disoproxil fumarate, teriparatide, tetramethylpyrazine, teverelix, tiotropium bromide, tipifarnib, tirapazamine, tolvaptan, TransvaxTM hepatitis C vaccine, treprostinil sodium; Valganciclovir hydrochloride, valsartan/amlodipine, vandetanib, vardenafil hydrochloride hydrate, vatalanib succinate, veglin, voriconazole; Yttrium 90 (90Y) ibritumomab tiuxetan; Zileuton, zotarolimus, zotarolimus-eluting stent.
临床试验指南是当前文献和会议中最新临床试验的指南。下表中的数据取自药物研发门户网站Prous Science Integrity的临床试验知识领域，网址为http://integrity.prous.com 本期重点关注以下药物选择：A - 007、A6、阿达木单抗、三磷酸腺苷、阿法赛特、阿仑单抗、变应原疫苗（豚草）、安福瑞、阿那白滞素、血管紧张素 -（1 - 7）、阿尼芬净、阿波明、阿立哌唑、盐酸托莫西汀、阿伐那非；BAL - 8557、贝卡替林、贝伐单抗、双相门冬胰岛素、BMS - 188797、硼替佐米、波生坦、B型肉毒毒素、溴夫定；卡泊三醇/倍他米松二丙酸酯组合、醋酸卡泊芬净、卡妥索单抗、赛妥珠单抗、西妥昔单抗、CG - 0070、环索奈德、盐酸西那卡塞、磷酸克林霉素/过氧化苯甲酰、隐藻素52、西罗莫司洗脱支架；达比加群酯、达拉匹林、达贝泊汀α、地西他滨、地拉罗司、地氯雷他定、右吗拉胺、右美沙芬/硫酸奎尼丁、二甲基富马酸、重组人活化蛋白C、盐酸度洛西汀；E - 7010、依达拉奉、依法利珠单抗、恩曲他滨、恩替卡韦、依普利酮、盐酸厄洛替尼、草酸艾司西酞普兰、戊酸雌二醇/地诺孕素、艾司佐匹克隆、艾塞那肽、依折麦布；磺达肝癸钠、氟维司群；吉非替尼、孕二烯酮、GYKI - 16084；透明质酸、盐酸肼屈嗪/硝酸异山梨酯；甲磺酸伊马替尼、因地普隆、甘精胰岛素；十全大补汤；拉米夫定/齐多夫定/硫酸阿巴卡韦、盐酸L - 精氨酸、酒石酸拉索昔芬、L - BLP - 25、来那度胺、左西替利嗪、左旋多巴/卡比多巴/恩他卡朋、来沙妥单抗、利多卡因/丙胺卡因、鲁比前列酮、氯美昔布；单克隆抗体 - 14.18、米托喹酮；那他珠单抗、奈立膦酸、神经放射；奥帕膦酸钠盐、奥马珠单抗；p53 - DC疫苗、甲状旁腺激素（重组人）、聚乙二醇化干扰素α - 2a、聚乙二醇化干扰素α - 2b、培美曲塞二钠、哌立福新、吡美莫司、普拉睾酮、普拉格雷、PRO - 2000、假他汀；R24、拉布立酶、RHAMM R3肽、利罗那肽、瑞舒伐他汀钙、轮状病毒疫苗、卢非酰胺；盐酸沙巴鲁比星、SHL - 749、西罗莫司洗脱支架、SLx - 2101、丁酸钠、索拉非尼、SU - 6668；速即纱、他达拉非、紫杉醇洗脱支架、马来酸替加色罗、替比夫定、富马酸替诺福韦二吡呋酯、特立帕肽、川芎嗪、特维雷利克斯、噻托溴铵、替匹法尼、替拉扎明、托伐普坦、丙型肝炎病毒疫苗、曲前列尼尔钠；盐酸缬更昔洛韦、缬沙坦/氨氯地平、凡德他尼、盐酸伐地那非水合物、琥珀酸瓦他拉尼、维格林、伏立康唑；钇90（90Y）替伊莫单抗；齐留通、佐他莫司、佐他莫司洗脱支架。
Zotero 插件